Bioactive nanotherapeutic trends to combat triple negative breast cancer

Area of Science:

• Oncology
• Nanomedicine
• Biotechnology

Background:

• Aggressive breast cancer, particularly triple-negative breast cancer (TNBC), presents significant management challenges.
• Current therapies offer limited survival benefits despite advancements.
• There is a critical need for strategies to improve drug bioavailability, targeting, and reduce toxicity.

Purpose of the Study:

• To review nanoparticle technology for delivering chemotherapeutic agents in breast cancer treatment.
• To document novel strategies using biomimetic nanoparticles for clinical translation.
• To highlight safe and actively targeted nanomedicines for breast cancer, especially TNBC.

Main Methods:

• Review of existing literature on nanoparticle-mediated drug delivery for breast cancer.
• Analysis of strategies employing cellular and cell membrane-cloaked (biomimetic) nanoparticles.
• Evaluation of approaches to enhance bioavailability, targetability, and reduce systemic toxicity.

Main Results:

• Nanoparticle drug delivery systems show promise for enhancing breast cancer treatment efficacy.
• Biomimetic nanoparticles offer a strategy for improved targeting and reduced side effects.
• These nanotechnologies represent a potential advancement in managing aggressive breast cancers like TNBC.

Conclusions:

• Nanoparticle-based therapies, including biomimetic approaches, are crucial for advancing breast cancer treatment.
• These strategies can improve the therapeutic outcomes of existing FDA-approved regimens.
• Nanomedicine offers a promising avenue for safer and more effective breast cancer management, particularly for TNBC.